The label answer, which surprises people
Lilly is more specific than most maintenance arguments assume: the label maintenance doses of Zepbound are 5 mg, 10 mg and 15 mg. The 7.5 and 12.5 mg pens exist as titration steps on the way up, not as intended long-term doses, a point Lilly makes explicitly in its medical answers. And 2.5 mg is named as a starting dose, not a therapeutic one. So “what is the maintenance dose” has an official answer, three of them, and none of the official answers is the one the cost-conscious corner of the community actually wants to hear about.
The trial answer: staying on some dose is what the evidence supports
SURMOUNT-4 is the trial built for exactly this question. Everyone took tirzepatide for 36 weeks and reached the 10 or 15 mg range; then half continued and half were switched to placebo. Over the following year, the continuers lost roughly another 5%, while the placebo group regained most of what they had lost. Roughly nine in ten people who stayed on the medication held at least 80% of their loss; on placebo, about one in six managed that. Counting from the very first injection to week 88, the continuers ended at about 25% total body weight reduction, the switched group at about 10%. That is the strongest evidence in the class that ongoing signal maintains the result, and it is worth noticing that continuing did not merely hold the line, it kept adding to it.
Read carefully, SURMOUNT-4 answers “does continuing work?” and stops there. It does not test 5 mg against 15 mg for maintenance, or weekly against stretched intervals, or medication against medication-plus-structure. Everything below the reached dose is practice running ahead of research, which does not make it wrong, but does make your own weekly trend the most important dataset you have.
The three patterns the community actually runs
Spend an evening in the maintenance subs and the same three shapes repeat, whatever the starting dose:
- Hold the rung that got you there. The SURMOUNT-4 pattern, and the one with trial support. The trade is carrying full cost and side effects into a phase where the goal is defense, not loss.
- Step down and watch. Drop a rung, hold it for four to eight weeks, and let the weekly average and the food noise decide whether the lower dose is enough. Reversible by design, which is what makes it a reasonable experiment to run with a prescriber.
- Stretch the interval. Same pen, every 10 to 14 days. The most common cost-driven pattern and the least studied. With a roughly 5-day half-life, day 12 sits far down the decay curve, which is why the community reports appetite waking before the next shot. Our washout calculator will draw exactly what a 14-day gap looks like.
There is a fourth pattern, true microdosing below 2.5 mg via compounded product, which is its own contested territory: the microdosing chart lays out the tiers and the evidence grade for each, and the generic maintenance-dose guide covers the taxonomy across all the GLP-1s.
The insurance reality, which quietly decides most of this
Read the maintenance subs closely and the dose debate is often not really about pharmacology; it is about coverage. Three patterns repeat. First, plans that covered the loss phase get twitchy at goal weight: reauthorizations ask why you still need the drug, and denial at renewal is one of the most common ways people end up stopping with two weeks’ notice. Second, people stretch intervals or step down not because they think it is optimal but because it makes a covered supply, or a self-pay budget at several hundred dollars a month, go further. Third, stopping entirely and planning to restart if needed is riskier than it sounds on paper: a restart can mean a fresh prior authorization, a new titration from the bottom of the ladder, and months of ground lost in between. None of this is medical advice; it is the terrain. It rewards knowing your plan’s renewal criteria before the renewal, and having your trend data ready to show that the medication is doing measurable work.
Stepping down without guessing: run it like an experiment
The community pattern that goes worst is changing everything at once and navigating by vibes. The pattern that goes best looks like an experiment, and it is simple to copy:
- Change one variable. Drop one rung, or widen the interval, never both in the same move. If two things change and the trend drifts, you cannot tell which one did it.
- Give it four to eight weeks. Weekly injections take about a month to settle at a new steady level, and a weight trend needs a few weeks beyond that to mean anything. Shorter reads are noise.
- Watch two signals only: the weekly average against your line, and whether food noise stays quiet. Daily weights and single loud evenings are not data.
- Pre-commit the revert trigger. Decide before the change what sends you back up a rung, for example the weekly average crossing your line for two consecutive weeks. Deciding in advance removes the bargaining later.
- Tell your prescriber the plan, including the trigger. A described experiment with a defined abort condition is an easy yes; a vague wish to take less medication is a hard conversation.
The part the dose decision cannot do
Whichever rung you hold, maintenance has jobs the pen does not cover: a protein floor near 1.6 g per kg of goal weight (the protein calculator gives the number), two or three strength sessions to keep the muscle you paid for, fiber that the maintenance subs swear by more than any supplement, and a watched weekly average against a line you chose. Drift caught at 3 lbs is a dose conversation; drift discovered at 15 is a crisis. If the plan is eventually to come off entirely, keeping the weight off after Zepbound is that playbook.